File downloaded on 2026-11-09
Source URL: https://medicines.health.europa.eu/veterinary/en/600001874632

Trilocur 50 mg/ml - Oral suspension

Authorised

- Trilostane

Product identification

Medicine name:
Trilocur 50 mg/ml - Oral suspension

Active substance:
Trilostane

Target species:
Dog

Route of administration:
Oral use

Product details

Active substance and strength:
Trilostane
50.00 milligram(s) / 1.00 millilitre(s)

Pharmaceutical form:
Oral suspension

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QH02CA01

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

Austria , Belgium , Bulgaria , Croatia , Cyprus , Czechia , Denmark , Estonia , Finland , France , Germany , Greece , Hungary , Iceland , Ireland , Italy , Latvia , Liechtenstein , Lithuania , Luxembourg , Malta , Netherlands , Norway , Poland , Portugal , Romania , Slovakia , Slovenia , Spain , Sweden , United Kingdom (Northern Ireland)

Available in:

Austria , Belgium , Cyprus , Czechia , Denmark , Germany , Greece , Hungary , Ireland , Italy , Luxembourg , Netherlands , Poland , Romania , Slovakia , Slovenia , United Kingdom (Northern Ireland)

Package description:

Packaging:Bottle (HDPE) with 1 ml and 5 ml syringe (PP), Package_size:1 bottle, Content:10 ml

Packaging:Bottle (HDPE) with 1 ml and 5 ml syringe (PP), Package_size:1 bottle, Content:50 ml

Packaging:Bottle (HDPE) with 1 ml and 5 ml syringe (PP), Package_size:1 bottle, Content:100 ml

Packaging:Bottle (HDPE) with 1 ml and 5 ml syringe (PP), Package_size:1 bottle, Content:25 ml

Packaging:Bottle (HDPE) with 1 ml and 5 ml syringe (PP), Package_size:1 bottle, Content:36 ml

Packaging:Bottle (HDPE) with 1 ml and 5 ml syringe (PP), Package_size:1 bottle, Content:72 ml

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:
Hybrid application – change in pharmaceutical form (Article 19(1)(a) of Regulation (EU) 2019/6)

Marketing authorisation holder:
Emdoka

Marketing authorisation date:
6/05/2024

Manufacturing sites for batch release:
Lelypharma B.V.

Responsible authority:
European Commission

Authorisation number:
This information is not available for this product.

Date of authorisation status change:
6/05/2024

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Combined File of all Documents

English (PDF)
Published on: 13/03/2026
Download

ema-puar-v6128-trilocur-en.pdf